ITI Pharma and Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: NIFTY Healthcare Total Return Index.Check Portfolio Overlap →
NAV: ₹19.93+0.41%
07 Sept 2026
Similar Funds
Side-by-side comparison of ITI Pharma and Healthcare Fund Direct-Growth with similar funds — trailing returns, risk metrics, AUM and expense ratio.
| Period | This Fund | Category Avg | Category Rank |
|---|---|---|---|
| 1Y Return | +13.63% | 18.26% | 17 / 21 |
| 3Y Return | +19.87% | 22.79% | 10 / 11 |
| 5Y Return | — | 15.66% | — |
| 10Y Return | — | 15.35% | — |
Trailing annualised returns (%). Category rank: lower is better. Green = top third of category.
Funds in Equity: Sectoral-Pharma
Top funds by AUM in the Equity: Sectoral-Pharma category — see how ITI Pharma and Healthcare Fund Direct-Growth compares on size and returns.
Funds Tracking NIFTY Healthcare Total Return Index.
Top funds tracking the NIFTY Healthcare Total Return Index. — sorted by AUM to show the largest options available.
Frequently Asked Questions
Which funds are similar to ITI Pharma and Healthcare Fund Direct-Growth?
Funds similar to ITI Pharma and Healthcare Fund Direct-Growth in the Equity: Sectoral-Pharma category include Nippon India Pharma Fund Direct-Growth, ICICI Prudential Healthcare Fund Direct-Growth, and SBI Healthcare Opportunities Fund Direct Plan-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.
What is the rank of ITI Pharma and Healthcare Fund Direct-Growth in its category?
On a 3-year return basis ITI Pharma and Healthcare Fund Direct-Growth is ranked 10 out of 11 funds in the Equity: Sectoral-Pharma category as of 6 Sep 2026. Consistently ranking in the top across multiple time periods is a stronger signal of fund quality than a single-period rank.
How does ITI Pharma and Healthcare Fund Direct-Growth's expense ratio compare to similar funds?
ITI Pharma and Healthcare Fund Direct-Growth has an expense ratio of 0.92%. The peers Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99% and ICICI Prudential Healthcare Fund Direct-Growth has 1.31%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.
How does ITI Pharma and Healthcare Fund Direct-Growth's AUM compare to similar funds?
ITI Pharma and Healthcare Fund Direct-Growth has an AUM of ₹262.84 crore. The peers Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,279.11 crore and ICICI Prudential Healthcare Fund Direct-Growth has ₹6,802.61 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.
Which fund has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is UTI Healthcare Fund Direct-Growth with a CAGR of 24.47% as of 6 Sep 2026. ITI Pharma and Healthcare Fund Direct-Growth has delivered 19.87% CAGR over the same period, ranking 10 out of 11 funds. You can view and compare the full category ranking on sharpely.
How does ITI Pharma and Healthcare Fund Direct-Growth rank in risk-adjusted returns vs peers?
On a risk-adjusted basis, ITI Pharma and Healthcare Fund Direct-Growth has a Sharpe ratio of 0.91 compared to the Equity: Sectoral-Pharma average of 1.04 as of 6 Sep 2026. It ranks 12 out of 13 funds in its category on Sharpe ratio.